ViiV secures key phase III win for once-monthly injectable HIV regimen
On August 15, ViiV Healthcare revealed that cabotegravir/rilpivirine, its investigational two-drug, once-monthly injectable regimen to...
Read More...
Focus:
-
![]()
The People vs Big Pharma: tackling the industry’s trust issues
Price hikes, manipulative patent litigation and a rampant opioid addiction epidemic have steadily soured the...
Read More...
-
![]()
Reports of adverse events in Phase III AMD trials of Allergan’s abicipar
Allergan’s abicipar pegol may have cases of hemorrhagic vasculitis in its pivotal Phase III studies CEDAR...
Read More...
-
![]()
So you want to break into the Chinese vaccine market?
Last week, one of China’s largest vaccine makers, Changchun Changsheng Biotechnology, was exposed for selling...
Read More...
-
![]()
After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics
On July 24, Nabriva Therapeutics announced the acquisition of Zavante Therapeutics, a biotechnology company developing...
Read More...
-
![]()
EMA gives PRIME status to promising Huntington’s treatment
PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the development of...
Read More...
-
![brexit]()
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
The Medicines Health Products Regulatory Agency has reaffirmed its commitment to follow the European Clinical...
Read More...
-
![]()
Hackers can fool doctors with fake vital signs, but only the rich and powerful need to worry
It sounds like something out of a thriller: a hacker sneaks into the hospital room...
Read More...
-
![]()
Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth
Genentech has signed a $1bn open-ended drug discovery collaboration with Lodo Therapeutics to develop unique,...
Read More...
-
![]()
Pfizer/Lilly’s Phase III trial for tanezumab in osteoarthritis still draws caution
Pfizer and Eli Lilly’s tanezumab for osteoarthritis (OA) of the hip and knee may face...
Read More...
